Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
20/20 Biolabs's Business Segments
20/20 Biolabs's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
3
Largest Segment
One Test
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- One Test0%
- Bio Check7.7%
- CLI Ax3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| One Test | $ 1 | - |
| Bio Check | $ 0 | 7.7% |
| CLI Ax | $ 0 | 3% |
Revenue by Product & Service Category - FY
- One Test95.3%
- Bio Check4.8%
- CLI Ax0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| One Test | $ 1 | 95.3% |
| Bio Check | $ 0 | 4.8% |
| CLI Ax | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Annual Results
Revenue Share by Reportable Segment - FY
- One Test0%
- Bio Check7.7%
- CLI Ax3%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| One Test | $ 1 | - |
| Bio Check | $ 0 | 7.7% |
| CLI Ax | $ 0 | 3% |
Description of 20/20 Biolabs
20/20 Biolabs, Inc. develops and commercializes AI-powered laboratory blood tests for early detection and prevention of cancers and chronic diseases. Its main products are two test families under the OneTest brand: OneTest for Cancer, a multi-cancer early detection (MCED) test, and OneTest for Longevity, which measures inflammatory biomarkers and is also marketed as OneTest for Workplace Wellness to self-insured employers. Both tests are performed in the company's CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland, which also hosts the Clinical Laboratory Innovation Accelerator (CLIAx), a shared CLIA laboratory for overseas diagnostics startups. The company’s legacy product, BioCheck, is a field test kit for screening suspicious powders for bioterror agents. OneTest for Cancer, which generates the majority of the company's revenue, is a protein tumor marker-based MCED test that offers lower cost (under $200), ease of use with small capillary blood samples, and early-stage cancer detection advantages compared to ctDNA-based tests. This test combines protein biomarkers with patient information and serves as a preliminary screening tool to identify individuals requiring follow-up testing. OneTest Premium, licensed from BioInfra Life Science, Inc., includes additional biomarkers and estimates likelihoods for eight specific tumor types. The company is pursuing Medicare coverage for its MCED test and benefits from legislative support for firefighter cancer screening programs.